Cho KY, et al. - In patients with type 2 diabetes mellitus, the effects of dapagliflozin (DAP) and pioglitazone (PIO) on body weight and glycaemic control were compared. For this 24-week, open-label, prospective, randomized, parallel-group comparison study, 71 patients on PIO were either switched to DAP at 5 mg per day or continued on PIO. According to the findings, the reduction in body weight was greater with DAP than with PIO. Findings suggested that DAP promotes loss of body weight in type 2 diabetes mellitus and can reduce fluid retention, thereby reducing cardiovascular events.